Investigating how layilin affects platelet function in inflammatory bowel disease
Layilin as a modulator of platelet activation and thromboinflammation
This study is looking at how a special receptor called layilin affects platelets in people with inflammatory bowel disease (IBD), with the hope of finding new ways to treat IBD that are easier and less invasive.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-10937996 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of a specific receptor called layilin in platelets, particularly in patients with inflammatory bowel disease (IBD). The study aims to explore how layilin influences platelet behavior and its interaction with hyaluronan, a component that plays a role in inflammation. By examining both human patients and mouse models, the researchers hope to identify potential therapeutic targets that could lead to non-invasive treatments for IBD. The ultimate goal is to improve patient outcomes by addressing the underlying mechanisms of platelet dysfunction in IBD.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with inflammatory bowel disease who experience platelet dysfunction.
Not a fit: Patients without inflammatory bowel disease or those who do not exhibit platelet dysfunction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new non-invasive treatment options for patients suffering from inflammatory bowel disease.
How similar studies have performed: While the specific focus on layilin in platelets is novel, previous research has shown success in targeting other receptors for therapeutic purposes in similar inflammatory conditions.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Mellema, Rebecca — University of Utah
- Study coordinator: Mellema, Rebecca
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.